Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals : U.S. buys additional doses of Eli Lilly, Regeneron COVID-19 therapy

09/15/2021 | 07:27am EDT

Sept 15 (Reuters) - Eli Lilly and Company said on Wednesday the U.S. government bought 388,000 additional doses of its COVID-19 antibody therapy, as infections surge due to the fast-spreading Delta variant.

The news comes after Regeneron Pharmaceuticals Inc said late on Tuesday the U.S. government was buying 1.4 million additional doses of its COVID-19 antibody cocktail, REGEN-COV.

Lilly said its deal with the U.S government is expected to generate approximately $330 million in revenue in the second half of 2021, with about 200,000 doses expected to be shipped in the third quarter this year and the remaining in fourth.

"The recent increase in COVID-19 cases has caused a substantial rise in the utilization of monoclonal antibody drugs, particularly in areas of the country with low vaccination rates," Lilly's chief scientific and medical officer Daniel Skovronsky said.

The drugmaker will supply additional doses of etesevimab to be paired with doses of its other COVID-19 antibody therapy, bamlanivimab, previously purchased by the U.S. government.

Bamlanivimab and etesevimab are authorized for use in people 12 years and above with mild-to-moderate infection and at high risk for progression to severe COVID-19. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)


© Reuters 2021
All news about REGENERON PHARMACEUTICALS
10/14REGENERON PHARMACEUTICALS : FDA Accepts Regeneron's 'Regen-Cov" For Priority Review for Tr..
MT
10/14Health Care Stocks Climb Pre-Bell Thursday
MT
10/14REGENERON PHARMACEUTICALS : US FDA Accepts Regeneron's Regen-Cov For Priority Review for C..
MT
10/14REGENERON PHARMACEUTICALS : FDA Accepts Regeneron's 'Regen-Cov" For Priority Review for Tr..
MT
10/14REGENERON PHARMACEUTICALS : FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priorit..
PR
10/14Regeneron Cocktail Gets FDA Priority Review for Covid-19 Treatment, Prevention
DJ
10/12REGENERON PHARMACEUTICALS : Morgan Stanley Adjusts Price Target on Regeneron Pharmaceutica..
MT
10/11REGENERON PHARMACEUTICALS : to Report Third Quarter 2021 Financial and Operating Results a..
PR
10/11EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisation
RE
10/11REGENERON PHARMACEUTICALS : EU assesses Regeneron/Roche COVID-19 antibody cocktail for aut..
RE
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 14 174 M - -
Net income 2021 7 088 M - -
Net cash 2021 10 057 M - -
P/E ratio 2021 8,36x
Yield 2021 -
Capitalization 57 519 M 57 519 M -
EV / Sales 2021 3,35x
EV / Sales 2022 3,60x
Nbr of Employees 9 635
Free-Float 82,0%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | MarketScreener
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 553,24 $
Average target price 681,18 $
Spread / Average Target 23,1%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS14.52%57 519
GILEAD SCIENCES, INC.16.08%84 795
BIONTECH SE203.83%59 820
WUXI APPTEC CO., LTD.28.00%57 897
VERTEX PHARMACEUTICALS-23.09%47 156
BEIGENE, LTD.38.72%33 452